Food

 

New Market Report: Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017



22.11.2017 14:35:05 - Recently published research from GBI Research, "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017", is now available at Fast Market Research

(live-PR.com) - YEAR-END RESEARCH SALE!
- This report might qualify for up to a 30% DISCOUNT if purchased before the end of 2017
- More details at www.fastmr.com/prod/1302747_neuropsychiatric_dis ..

This report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD),

 

Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.

The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope

* Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
* Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
* To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
* What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to Get this Report

* Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
* Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
* Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
* Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Browse our complete collection of Pharmaceuticals research reports at www.fastmr.com/catalog/browse.aspx?category=16&a ..

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)


Author:
Bill Thompson
e-mail
Web: http://www.fastmr.com
Phone: 1.413.485.7001


 

Disclaimer: If you have any questions regarding information in this article please contact the author. Please do not contact Live-PR.com. We are not able to assist you. Live-PR.com disclaims content contained in this article. Live-PR.com is not authorized to give any information about content and not responsible for content posted by third party.
refer this article
Print This Article
Terms Of Use Privacy About Live-PR.com Contact Us